Squamous Cell Carcinoma of the Lungs

Table of Contents
View All
Table of Contents

Squamous cell carcinoma of the lungs is one form of non-small cell lung cancer. Non-small cell lung cancers account for about 85% of lung cancers, and of these, roughly 30% are squamous cell carcinomas.

Squamous cell carcinoma begins in the tissues that line the air passages in the lungs. It is also known as epidermoid carcinoma. Most squamous cell carcinomas of the lungs are located centrally, usually in the larger bronchi that join the trachea to the lung.

squamous cell carcinoma
Verywell / Julie Bang


Common signs and symptoms of squamous cell carcinoma are not unlike those of other lung cancers and typically include:

  • A persistent cough
  • Shortness of breath
  • Wheezing
  • Coughing up of blood 
  • Fatigue
  • Discomfort when swallowing
  • Chest pain
  • Fever
  • Hoarseness
  • Loss of appetite
  • Unexplained weight loss of greater than 5% over a six- to 12-month period

But there's also a difference that distinguishes this form of cancer from others. Squamous cell carcinoma tends to cause symptoms earlier because it affects the larger airways of the lungs (as opposed to adenocarcinoma which affects the edges). While this translates to higher rates of early detection, 75% of cases are still only diagnosed after the cancer has spread.

Squamous cell carcinoma is the most common cause of Pancoast syndrome (also known as superior sulcus syndrome). Pancoast syndrome is caused by cancers that begin near the top of the lungs and invade nearby structures, such as nerves. Symptoms include shoulder pain that radiates down the inside of the arm, weakness or prickly sensations in the hands, flushing or sweating on one side of the face, and a droopy eyelid (Horner’s syndrome).

Individuals with squamous cell carcinoma are also more likely to experience an elevated calcium level (hypercalcemia) which can result in muscle weakness and cramps. Hypercalcemia is one of the symptoms of paraneoplastic syndrome and is caused by a tumor secreting a hormone-like substance that raises the calcium level in the blood.


Squamous cell carcinomas are linked more strongly with smoking than other forms of non-small cell lung cancers and are more common in men than in women.

A 2010 report from John Hopkins University suggested that as many as 91% of squamous cell lung cancers are attributed to cigarettes and that the degree of risk is directly linked to the number of cigarettes smoked per day.

While squamous cells carcinomas are intrinsically linked to smoking, other causes can contribute. Among these, radon exposure in the home is the second leading cause of lung cancer. Occupational exposures to diesel fuel and other toxic fumes and gases are also important risk factors.

Genetics may also play a role given that the risk is statistically increased in people who have other family members with lung cancer.

The incidence of squamous cell carcinoma of the lungs has been decreasing in recent years, whereas the rate of adenocarcinoma has been increasing. It is thought that the addition of filters to cigarettes allows smoke to be inhaled more deeply into the lungs where adenocarcinomas tend to develop These cancers can, however, occur even in people who have never smoked.


Squamous cell carcinoma of the lungs is often first suspected when abnormalities are seen on an X-ray. Further evaluation may include:

  • Chest CT scan (a form of X-ray that produces cross-sectional images of the lungs)
  • Sputum cytology (which tends to be effective given that cancer cells are more readily dislodged from the large airways)
  • Bronchoscopy (a direct form of visualization in the lungs)
  • PET scan (which is better able to detect current cancer activity)
  • Endobronchial ultrasound (involving an ultrasound probe inserted into the windpipe)

Depending on the results, your healthcare provider may want to obtain a sample of tissue (lung biopsy) to confirm the diagnosis and will order further tests to check to see if your cancer has spread.

Disease Staging

If cancer is confirmed, your healthcare provider will next want to stage the malignancy. Squamous cell carcinoma of the lungs is broken down into four stages:

  • Stage 1: the cancer is localized and has not spread to any lymph nodes
  • Stage 2: the cancer has spread to lymph nodes or the lining of the lungs, or is in a certain area of the main bronchus
  • Stage 3: the cancer has spread to tissue near the lungs
  • Stage 4: the cancer has spread (metastasized) to another part of the body, the most common sites being the bones, brain, liver, or adrenal glands

Healthcare providers will also use more a complex means of staging called TNM staging. With this, they will look at the size of the tumor (represented by a T); the number and locations of nodes affected (N), and whether the tumor has metastasized (M).


Squamous cell lung cancers can be further divided into four subtypes based on how they look under a microscope and how they behave. The pathologist will then classify the cancer as either:

  • Primitive
  • Classical
  • Secretory
  • Basal

Survival rates vary significantly between the subtypes, with primitive carcinomas having the poorest outcomes overall. The subtypes are also important in that they help healthcare providers determine which drug regimen they are most likely to respond to. Most subtypes respond to at least one of the commonly used chemotherapy drugs.

The only exception may be secretory squamous cell lung cancer. This subtype is less sensitive to commonly used drugs because it tends to be slow-growing. By and large, chemotherapy is most effective in targeting and destroying cancers with fast-dividing cells. 


Depending upon the stage of squamous cell carcinoma of the lungs, treatment may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, or a combination of these. Many clinical trials are in progress looking for new ways to treat this cancer and to help decide which treatments are most effective.

Often times in the past, these different categories of treatment were used separately. For example, with metastatic squamous cell tumors, first-line therapy usually included either an immunotherapy drug or chemotherapy, but combination therapy may prove most beneficial.

A 2018 study published in The New England Journal of Medicine found that using the combination of the immunotherapy drug Keytruda (pembrolizumab) with chemotherapy significantly prolonged overall survival for people with metastatic squamous cell cancers of the lung.


Lung cancer surgery may be possible for squamous cell carcinoma. With stage 1A squamous cell lung cancer, surgery alone may be curative. Surgery may also be considered for those with stage 1B, stage 2, and stage 3A lung cancer, usually combined with chemotherapy and radiation therapy. Sometimes, a tumor may initially be inoperable but may be reduced in size with chemotherapy and/or radiation therapy so that surgery is then possible.

When chemotherapy is done to reduce the size of a tumor prior to surgery it is referred to as "neoadjuvant chemotherapy." Recently, success has been demonstrated in using immunotherapy to reduce the size of an inoperable tumor so that surgery may be performed.


Chemotherapy may be used alone, in conjunction with radiation therapy, or before or after surgery for lung cancer. It may also be combined with immunotherapy, and this combination appears to have the most benefit on survival in those who have metastatic disease. Squamous cell carcinoma of the lungs responds somewhat differently to chemotherapy medications than other lung cancers, such as adenocarcinoma.

Common medications used initially for this type of cancer include Platinol (cisplatin) and Gemzar (gemcitabine). For those who respond to treatment, continuous (maintenance treatment) with Tarceva (erlotinib) or Alimta (pemetrexed) may be used.

First-line chemotherapy typically consists of platinum-based drugs like Platinol, Paraplatin (carboplatin), or Eloxatin (oxalaplatin). Compared to non-platinum-based drugs, these agents are more likely to achieve complete remission, according to a 2015 Cochrane review.

Radiation Therapy

Radiation therapy may be used to treat cancer or to control symptoms related to the spread of cancer. Radiation may be given externally, or internally (brachytherapy) in which radioactive material is delivered to a precise area of the lungs during a bronchoscopy.

Targeted Therapy

You may have heard about the use of targeted drugs to treat EGFR mutations in lung adenocarcinoma. EGFR, or epidermal growth factor receptor, is a protein involved in driving the growth of a cancer. Squamous cell carcinoma of the lungs may also be treated by targeting the EGFR pathway, but by a different mechanism.

Instead of targeting EGFR mutations, anti-EGFR antibodies are a class of drugs used to bind to EGFR on the outside of cancer cells. When EGFR is thus bound, the signaling pathway which tells the cell to grow is halted. Portrazza (necitumumab) was approved in 2015 to use along with chemotherapy for advanced squamous cell cancers. Clinical trials are evaluating other drugs, such as afatinib and more for the treatment of squamous cell lung cancer.


Immunotherapy drugs were first approved for the treatment of lung cancer in 2015, and now combinations of these drugs are being studied in clinical trials.

In 2015, the first immunotherapy treatment was approved for people with this disease. The medication Opdivo (nivolumab) is a form of immunotherapy that, very simplistically, enhances our body's own immune system's ability to fight off cancer cells.

To understand how these drugs work, it may help to think of your immune system as a car. The "brakes" are controlled by a protein called PD-1. Opdivo in this analogy works to block PD-1—the brakes—allowing the immune system to fight against the cancer without interference—in essence, taking the brakes off the car.

Immunotherapeutic drugs are currently approved for people with a metastatic non-small cell lung malignancy whose cancer has progressed during or after platinum-based chemotherapy.

A number of other immunotherapy drugs have since been approved, including Keytruda (pembrolizumab) and Tecentriq (atezolizumab).

As noted above, for metastatic squamous cell carcinoma, the combination of Keytruda and chemotherapy greatly improved survival.


Before answering the question “what is the prognosis of squamous cell lung cancer?” it is important to talk about what the numbers describing survival rate really mean. First of all, everyone is different.

Statistics tell us what the “average” course or survival is, but they don’t tell us anything about specific individuals. Many factors can affect the prognosis of squamous cell lung cancer including your age at diagnosis, your sex, the condition of your general health, and how you respond to treatments.

It is also helpful to keep in mind that statistics are based on information that is several years old. As new treatments become available, these numbers may not accurately reflect what your prognosis is today.

For example, the five-year survival rate for lung cancer reported in 2018 is based on people who were diagnosed in 2013 and earlier. Since many significant treatments for squamous cell carcinoma of the lung were only approved after 2013, statistics are not necessarily indicative of how someone will do today.

At the same time, there have been more new treatments approved for lung cancer in the last five years than in the previous 40 years. For example, the drug Portrazza was not available when the people in these studies were diagnosed. What this means is that the current reported survival rates fail to take into account how someone will be expected to do on any of these new treatments.

There is a lot of hope for those diagnosed with lung cancer today, but unfortunately, the statistics you will read may not be helpful in understanding this hope.

Five-year survival rates range from an average of 50% with stage 1 non-small cell lung cancer to only 2% to 4% by stage 4. Because most diagnoses are made in the later stages, the overall five-year survival rate is 18%.

It is important to note that many people treated for lung cancer live well in excess of five years and that advances in treatment are promising higher rates of sustained remission.


A diagnosis of squamous cell carcinoma of the lungs is frightening and you may feel very alone. The phrase "it takes a village" was never more appropriate than when talking about lung cancer. Reach out and allow (that part is sometimes the key) your loved ones to support you. 

Take the time to learn about your cancer. Studies tell us that people who better understand their cancer not only feel more empowered, but that knowledge can sometimes make a difference in survival as well. For example, not all oncologists may be familiar with the latest study showing significantly improved survival with metastatic disease for people initially treated with a combination of immunotherapy and chemotherapy. See if you can find a support group for people with lung cancer in your community, or take the time to connect with the wonderful lung cancer community online.

These people will not only welcome you in and support you but can be a great source of the latest information and research as well. Check out the lung cancer organizations such as LUNGevity, the American Lung Association Lung Force, and the Lung Cancer Alliance.

When searching for others with lung cancer on social media, the hashtag is #LCSM which stands for lung cancer social media. If you are under the age of 50, make sure to check out the Bonnie J. Addario Lung Cancer Foundation, an organization that takes a special interest in lung cancer in young adults.

Most of all, be your own advocate for your cancer care. The treatment of lung cancer is changing rapidly, and people are increasingly being called upon to be an active part of their treatment team. In fact, there are many survivors currently alive that are only alive because they educated themselves and were an advocate for their care.

Since general oncologists may not be abreast of fast-changing research, many lung cancer survivors recommend obtaining a second opinion from one of the larger National Cancer Institute-designated cancer centers.

A Word From Verywell

Coping with lung cancer in a loved one can be a challenge. Not only are you facing what your loved one is from your angle, but the sense of helplessness can be heart-wrenching. You can be reassured that most people have no idea how to react when a loved one has lung cancer.

Asking about specific ways in which you can help, rather than saying "call me if you need me," is a way in which you can express your caring and lessen their burden. Take a moment to learn what is really like to live with lung cancer and how you can better support a loved one with cancer.

Was this page helpful?
11 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi:10.21037/tlcr.2016.06.07

  2. American Cancer Society. Signs and symptoms of lung cancer.

  3. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645-53. doi:10.6004/jnccn.2013.0084

  4. Centers for Disease Control and Prevention. What are the risk factors for lung cancer?

  5. LUNGevity. Squamous cell lung cancer.

  6. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865

  7. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2015;(8):CD006849. doi:10.1002/14651858.CD006849.pub3

  8. Fala L. Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am Health Drug Benefits. 2016;9(Spec Feature):119-22.

  9. National Cancer Institute. FDA approves first immunotherapy treatment for lung cancer.

  10. Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39-50. doi:10.3978/j.issn.2218-6751.2016.01.03

  11. Bailo L, Guiddi P, Vergani L, Marton G, Pravettoni G. The patient perspective: investigating patient empowerment enablers and barriers within the oncological care process. Ecancer. 2019;13:912. doi:10.3332/ecancer.2019.912

Additional Reading